LABU

Leveraged & Inverse Channel

A Big Week for Betting On the CURE for Cancer

A Big Week for Betting On the CURE for Cancer

By DirexionJune 8, 2019

Leveraged & Inverse Channel

5 Leveraged ETFs With Biggest 1-Month Fund Flows

5 Leveraged ETFs With Biggest 1-Month Fund Flows

By Ben HernandezMay 22, 2019

Leveraged & Inverse Channel

Stock ETF Outpaces Bond ETF Interest For By $18B April

Stock ETFs Outpace Bond ETF Interest By $18B April

By Ian YoungMay 6, 2019

Leveraged & Inverse Channel

5 Best-Performing Leveraged ETFs Year-to-Date

5 Best-Performing Leveraged ETFs Year-to-Date

By Ben HernandezMarch 29, 2019

Leveraged & Inverse Channel

More Biopharma Mergers Could Fuel these ETFs in 2019

Big Biopharma Mergers Could Fuel These ETFs in 2019

By Ben HernandezJanuary 10, 2019

Leveraged & Inverse Channel

Biotech ETFs Hoping This Post-Election Trend Doesn't Repeat

Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat

By Brenton GarenNovember 8, 2018

Leveraged & Inverse Channel

After a Rough October, Leveraged Biotech ETF Looks to Bounce Back

After a Rough October, Leveraged Biotech ETF Looks to Bounce Back

By Brenton GarenNovember 6, 2018

Pharma, Biotech Bull ETFs Leading the Charge

Pharma, Biotech Bull ETFs Leading the Charge

By Ben HernandezJuly 12, 2018

Leveraged & Inverse Channel

5 Direxion ETFs to Keep an Eye on

5 Big Direxion ETFs Trending This Week

By Ben HernandezJune 22, 2018

Big Biotech ETF Can Bounce Back

Big Biotech ETF Can Bounce Back

By Tom LydonApril 18, 2018

Catalysts Abound for Biotech ETFs

Catalysts Abound for Biotech ETFs

By Tom LydonApril 10, 2018

Leveraging up Biotech ETFs

Betting Big on Biotech ETFs? Traders Leverage ETFs

By Brenton GarenMarch 28, 2018

Good Reasons to Stick With Biotech ETFs

Good Reasons to Stick With Biotech ETFs

By Tom LydonMarch 12, 2018

Healthcare Dip Could be a Buying Opportunity

Healthcare Dip Could be a Buying Opportunity

By Brenton GarenFebruary 5, 2018

Biotech ETFs Pop on Celgene, Juno Deal

Biotech ETFs Pop on Celgene, Juno Deal

By Max ChenJanuary 22, 2018

Adding Some Juice to the Healthcare Trade

Adding Some Juice to the Healthcare Trade

By Tom LydonJanuary 10, 2018

Biotech Slump Could be a Buying Opportunity

Biotech Slump Could be a Buying Opportunity

By Tom LydonDecember 5, 2017

Biotech Decline Could be a Buying Opportunity

Biotech Decline Could be a Buying Opportunity

By Brenton GarenNovember 16, 2017